Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dexamethasone Eye Drops in Proliferative Retinopathy of Prematurity
2023-505318-97-00Phase 3Authorised
- Sponsor
- Region Västra Götaland
- Start
- Aug 2023
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial in retinopathy of prematurity (ROP) comparing Dexamethasone eye drops with Placebo eye drops (2 arms). Primary endpoint: Progression to Type 1 ROP requiring conventional treatment. Planned start Aug 2023; status: authorised.
02
Drugs
dexamethasone
03
Conditions
retinopathy of prematurity (ROP)
Beyond the preview
Go deeper on 2023-505318-97-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505318-97-00.